5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...
21 April 2022 - Report will be subject of New England CEPAC meeting in January 2023; draft scoping document open ...
14 April 2022 - Final assessment to be published on 6 December 2022. ...
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...
8 March 2022 - Introductory information is designed to make RWE more accessible for health care audiences. ...
3 March 2022 - Report will be subject of New England CEPAC meeting in September 2022; draft scoping document open ...
3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through ...
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
9 February 2022 - Existing laws could be used to help make many drugs more affordable. ...
4 February 2022 - The field of cost effectiveness analysis has grown rapidly but in somewhat lopsided fashion. ...
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...